|
CZ2001584A3
(cs)
*
|
1998-08-18 |
2002-06-12 |
The Regents Of The University Of California |
Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
|
|
US6846799B1
(en)
*
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
DK1553097T3
(da)
|
1999-02-10 |
2010-12-13 |
Astrazeneca Ab |
Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
|
|
DZ3223A1
(fr)
*
|
1999-10-19 |
2001-04-26 |
Merck & Co Inc |
Inhibiteurs de tyrosine kinases
|
|
US6403581B1
(en)
*
|
2000-01-19 |
2002-06-11 |
American Cyanamid Company |
Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
|
|
US6420382B2
(en)
*
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
NZ522074A
(en)
|
2000-05-31 |
2004-06-25 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
|
US20020041880A1
(en)
*
|
2000-07-05 |
2002-04-11 |
Defeo-Jones Deborah |
Method of treating cancer
|
|
AR030357A1
(es)
*
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
|
ES2334641T3
(es)
|
2000-09-01 |
2010-03-15 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados aza heterociclicos y su uso terapeutico.
|
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
|
PL211125B1
(pl)
|
2000-09-11 |
2012-04-30 |
Novartis Vaccines & Diagnostic |
Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
|
|
WO2002032861A2
(en)
*
|
2000-10-17 |
2002-04-25 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
US20020198252A1
(en)
*
|
2001-05-24 |
2002-12-26 |
Joseph Payack |
Process for the preparation of alkylamine substituted indoles
|
|
WO2002100339A2
(en)
*
|
2001-06-13 |
2002-12-19 |
Biogal Gyogyszergyar Rt. |
Novel process for preparing rac-bicalutamide and its intermediates
|
|
US7102026B2
(en)
*
|
2001-06-13 |
2006-09-05 |
Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Process for preparing and isolating rac-bicalutamide and its intermediates
|
|
US7642278B2
(en)
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
|
US6872715B2
(en)
*
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
|
US6927293B2
(en)
*
|
2001-08-30 |
2005-08-09 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2003020699A2
(en)
*
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US7101884B2
(en)
*
|
2001-09-14 |
2006-09-05 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AU2002361577A1
(en)
*
|
2001-10-30 |
2003-05-12 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2003049740A1
(en)
*
|
2001-12-12 |
2003-06-19 |
Pfizer Products Inc. |
Quinazoline derivatives for the treatment of abnormal cell growth
|
|
DK1474420T3
(da)
|
2002-02-01 |
2012-05-21 |
Astrazeneca Ab |
Quinazolinforbindelser
|
|
US6822097B1
(en)
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
|
ATE326970T1
(de)
*
|
2002-02-22 |
2006-06-15 |
Us Gov Veterans Affairs |
Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
|
|
WO2003080061A1
(en)
*
|
2002-03-21 |
2003-10-02 |
Dana-Farber Cancer Institute, Inc. |
Inhibition of cell death responses induced by oxidative stress
|
|
GB0207362D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Univ Liverpool |
Chemotherapy
|
|
WO2003082271A2
(en)
|
2002-04-03 |
2003-10-09 |
Astrazeneca Ab |
Indole derivatives having anti-angiogenetic activity
|
|
US20050113577A1
(en)
*
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
|
US6770660B2
(en)
*
|
2002-05-06 |
2004-08-03 |
Artery Llc |
Method for inhibiting platelet aggregation
|
|
US20040127435A1
(en)
*
|
2002-08-02 |
2004-07-01 |
Regents Of The University Of California |
Uses for inhibitors of inosine monophosphate dehydrogenase
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
BR0313743A
(pt)
*
|
2002-08-23 |
2005-07-05 |
Chiron Corp |
Benzimidazol quinolinonas e usos destas
|
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
|
MXPA05004754A
(es)
*
|
2002-11-13 |
2005-08-02 |
Chiron Corp |
Metodos para tratar cancer y metodos relacionados.
|
|
AU2003284572A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Yamanouchi Pharmaceutical Co., Ltd. |
2-oxoindoline derivatives
|
|
US20060093666A1
(en)
*
|
2003-03-27 |
2006-05-04 |
Karki Shyam B |
Formulations for tyrosine kinase inhibitors
|
|
WO2004089930A1
(en)
*
|
2003-04-02 |
2004-10-21 |
Imclone Systems Incorporated |
4-fluoroquinolone derivatives and their use as kinase inhibitors
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
WO2005000833A1
(en)
*
|
2003-05-19 |
2005-01-06 |
Irm, Llc |
Immunosuppressant compounds and compositions
|
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
|
US20050054625A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
|
|
US20050020557A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
|
US20050054589A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
|
|
US20050020534A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
|
|
US20050026893A1
(en)
*
|
2003-05-30 |
2005-02-03 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
|
|
US20070054921A1
(en)
*
|
2003-06-05 |
2007-03-08 |
Davies Ian W |
Substituted indoles and a process for preparing substituted indoles
|
|
WO2005014825A2
(en)
|
2003-08-08 |
2005-02-17 |
Arriva Pharmaceuticals, Inc. |
Methods of protein production in yeast
|
|
WO2005047244A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Chiron Corporation |
Inhibition of fgfr3 and treatment of multiple myeloma
|
|
WO2005054183A2
(en)
*
|
2003-12-01 |
2005-06-16 |
The Scripps Research Institute |
Quinolinone based protein kinase inhibitors
|
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2005072766A2
(en)
*
|
2004-01-27 |
2005-08-11 |
Boys Town National Research Hospital |
Peptides that bind to hsp90 proteins
|
|
US7875624B2
(en)
*
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
|
AU2005221151A1
(en)
|
2004-03-09 |
2005-09-22 |
Arriva Pharmaceuticals, Inc. |
Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
|
|
EP2574341B1
(en)
|
2004-03-29 |
2017-03-29 |
University Of South Florida |
Effective treatment of tumors and cancer with triciribine phosphate
|
|
US20110008327A1
(en)
|
2004-03-29 |
2011-01-13 |
Cheng Jin Q |
Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
|
|
US20110223154A1
(en)
*
|
2008-05-12 |
2011-09-15 |
University Of South Florida |
Compositions including triciribine and methods of use thereof
|
|
US20100009928A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and taxanes and methods of use thereof
|
|
US20100173864A1
(en)
|
2004-03-29 |
2010-07-08 |
Cheng Jin Q |
Compositions including triciribine and one or more platinum compounds and methods of use thereof
|
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
|
US20100028339A1
(en)
|
2004-03-29 |
2010-02-04 |
Cheng Jin Q |
Compositions including triciribine and trastuzumab and methods of use thereof
|
|
EP1598348A1
(en)
*
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Novel pyridazinone derivatives as inhibitors of CDK2
|
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US20080096859A1
(en)
*
|
2004-10-01 |
2008-04-24 |
Sullivan Kathleen A |
Compositions and Methods for Treating Ophthalmic Diseases
|
|
PL2301546T3
(pl)
|
2005-01-27 |
2015-03-31 |
Novartis Ag |
Leczenie guzów z przerzutami
|
|
WO2007084135A2
(en)
*
|
2005-01-28 |
2007-07-26 |
Merck & Co., Inc. |
Inhibitors of checkpoint kinases
|
|
US7960548B2
(en)
*
|
2005-04-29 |
2011-06-14 |
The Ohio State University Research Foundation |
Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
|
|
CN101222850B
(zh)
|
2005-05-13 |
2012-10-03 |
诺瓦提斯公司 |
治疗对药物有抗性的癌症的方法
|
|
PT1888556E
(pt)
|
2005-05-17 |
2012-02-03 |
Novartis Ag |
Métodos para sintetizar compostos heterocíclicos
|
|
NZ563692A
(en)
*
|
2005-05-23 |
2011-04-29 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
|
|
WO2007058482A1
(en)
*
|
2005-11-16 |
2007-05-24 |
Lg Life Sciences, Ltd. |
Novel inhibitors of protein kinase
|
|
US8658633B2
(en)
*
|
2006-02-16 |
2014-02-25 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
|
TW200812615A
(en)
*
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
US8246966B2
(en)
*
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
|
US8338433B2
(en)
*
|
2006-11-22 |
2012-12-25 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetoplastid agents
|
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
|
SI2203439T1
(sl)
|
2007-09-14 |
2011-05-31 |
Ortho Mcneil Janssen Pharm |
1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
|
|
BRPI0817101A2
(pt)
|
2007-09-14 |
2017-05-09 |
Addex Pharmaceuticals Sa |
4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
CA2724246C
(en)
*
|
2008-05-12 |
2019-11-26 |
University Of South Florida |
Anticancer combination therapy including triciribine
|
|
WO2009156284A1
(en)
*
|
2008-06-24 |
2009-12-30 |
F. Hoffmann-La Roche Ag |
Novel substituted pyridin-2-ones and pyridazin-3-ones
|
|
ES2439291T3
(es)
|
2008-09-02 |
2014-01-22 |
Janssen Pharmaceuticals, Inc. |
Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
|
|
ES2401691T3
(es)
|
2008-11-28 |
2013-04-23 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
|
|
AU2010232729A1
(en)
|
2009-03-31 |
2011-10-20 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
|
TWI410418B
(zh)
|
2009-04-29 |
2013-10-01 |
Ind Tech Res Inst |
氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
|
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
ES2440001T3
(es)
|
2009-05-12 |
2014-01-27 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
|
|
SG176018A1
(en)
|
2009-05-12 |
2011-12-29 |
Janssen Pharmaceuticals Inc |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
LT2769737T
(lt)
|
2009-07-20 |
2017-06-26 |
Bristol-Myers Squibb Company |
Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
|
|
WO2011050069A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
|
KR100953511B1
(ko)
*
|
2009-12-28 |
2010-04-21 |
(주)지노믹트리 |
건선 진단용 키트 및 칩
|
|
US20130090371A1
(en)
*
|
2010-04-20 |
2013-04-11 |
President And Fellows Of Harvard College |
Methods and compositions for inhibition of beta2-adrenergic receptor degradation
|
|
ES2552455T3
(es)
|
2010-11-08 |
2015-11-30 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
|
|
CN103298809B
(zh)
|
2010-11-08 |
2016-08-31 |
杨森制药公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
|
CA2814998C
(en)
|
2010-11-08 |
2019-10-29 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
KR101511889B1
(ko)
|
2011-02-17 |
2015-04-13 |
네스텍 소시에테아노님 |
여과에 의해 백혈구 및 종양 세포를 단리하는 장비 및 방법
|
|
CA2871711A1
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
EP2875020B1
(en)
|
2012-07-19 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
|
|
EP3007689B1
(en)
|
2013-01-10 |
2018-03-07 |
Pulmokine, Inc. |
Non-selective kinase inhibitors
|
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
|
AR097102A1
(es)
|
2013-08-02 |
2016-02-17 |
Pfizer |
Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco
|
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
|
EP3054937B1
(en)
|
2013-10-11 |
2023-07-26 |
Pulmokine, Inc. |
Spray dry formulations
|
|
US10537573B2
(en)
|
2014-01-21 |
2020-01-21 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
|
IL279202B2
(en)
|
2014-01-21 |
2023-09-01 |
Janssen Pharmaceutica Nv |
Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
US10704104B2
(en)
|
2014-10-20 |
2020-07-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for screening a subject for a cancer
|
|
ES2764299T3
(es)
|
2014-12-09 |
2020-06-02 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales humanos contra AXL
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
JP2018525029A
(ja)
|
2015-07-07 |
2018-09-06 |
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） |
ミオシン１８ａに対する特異性を有する抗体およびその使用
|
|
ES2955775T3
(es)
|
2015-08-27 |
2023-12-07 |
Inst Nat Sante Rech Med |
Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
JP2019513008A
(ja)
|
2016-02-26 |
2019-05-23 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｂｔｌａに対して特異性を有する抗体及びその使用
|
|
IL305882B2
(en)
|
2016-05-25 |
2025-11-01 |
Inst Nat Sante Rech Med |
Methods for producing a population of inactivated pluripotent cells
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
JP7219207B2
(ja)
|
2016-07-29 |
2023-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
腫瘍関連マクロファージを標的化する抗体及びその使用
|
|
MA46570B1
(fr)
|
2016-10-21 |
2021-10-29 |
Ose Immunotherapeutics |
Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t
|
|
KR20230093341A
(ko)
|
2016-10-27 |
2023-06-27 |
풀모킨 인코포레이티드 |
폐고혈압을 치료하기 위한 병용 요법
|
|
EP3538140A1
(en)
|
2016-11-14 |
2019-09-18 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
EP3624798A1
(en)
|
2017-05-18 |
2020-03-25 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of mast cell diseases
|
|
WO2019072888A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
|
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
|
|
WO2019099336A1
(en)
|
2017-11-14 |
2019-05-23 |
Bristol-Myers Squibb Company |
Substituted indole compounds
|
|
CA3083158A1
(en)
|
2017-11-24 |
2019-05-31 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and compositions for treating cancers
|
|
EP3720974A1
(en)
|
2017-12-07 |
2020-10-14 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Method for screening a subject for a cancer
|
|
EA202091477A1
(ru)
|
2017-12-15 |
2020-10-28 |
Бристол-Маерс Сквибб Компани |
Замещенные соединения простых индольных эфиров
|
|
WO2019126081A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Bristol-Myers Squibb Company |
Amide substituted indole compounds useful as tlr inhibitors
|
|
CA3085761A1
(en)
|
2017-12-19 |
2019-06-27 |
Bristol-Myers Squibb Company |
Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists
|
|
JP7291145B2
(ja)
*
|
2017-12-19 |
2023-06-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｌｒ阻害剤として有効な置換されたインドール化合物
|
|
EP3728264B1
(en)
|
2017-12-20 |
2021-12-01 |
Bristol-Myers Squibb Company |
Diazaindole compounds
|
|
AU2018393003A1
(en)
|
2017-12-20 |
2020-08-06 |
Bristol-Myers Squibb Company |
Aryl and heteroaryl substituted indole compounds
|
|
EA202091480A1
(ru)
|
2017-12-20 |
2020-11-06 |
Бристол-Маерс Сквибб Компани |
Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
|
|
EP3775206A1
(en)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
JP2021521445A
(ja)
|
2018-04-13 |
2021-08-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
CA3101694A1
(en)
|
2018-05-30 |
2019-12-05 |
David MACHOVER |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
CN112703011A
(zh)
|
2018-08-06 |
2021-04-23 |
国家医疗保健研究所 |
用于治疗癌症的方法和组合物
|
|
EP3849602A1
(en)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
|
HUE066335T2
(hu)
|
2018-10-05 |
2024-07-28 |
Annapurna Bio Inc |
Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
|
|
US12172995B2
(en)
|
2018-10-24 |
2024-12-24 |
Bristol-Myers Squibb Company |
Substituted indole and indazole compounds
|
|
ES2963696T3
(es)
|
2018-10-24 |
2024-04-01 |
Bristol Myers Squibb Co |
Compuestos diméricos de indol sustituidos
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
EP3935193A1
(en)
|
2019-03-06 |
2022-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to diagnose a cmmrd
|
|
US12187723B2
(en)
|
2019-05-09 |
2025-01-07 |
Bristol-Myers Squibb Company |
Substituted benzimidazolone compounds
|
|
EP3972997A1
(en)
|
2019-05-20 |
2022-03-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Novel anti-cd25 antibodies
|
|
WO2021013712A1
(en)
|
2019-07-19 |
2021-01-28 |
Anagenesis Biotechnologies S.A.S. |
Polyaromatic urea derivatives and their use in the treatment of muscle diseases
|
|
EP4007820A1
(en)
|
2019-08-02 |
2022-06-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method for screening a subject for a cancer
|
|
CN114761404B
(zh)
|
2019-10-01 |
2025-02-21 |
百时美施贵宝公司 |
经取代的双环杂芳基化合物
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
JP7545467B2
(ja)
|
2019-10-04 |
2024-09-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
置換カルバゾール化合物
|
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
|
CN115551553A
(zh)
|
2020-05-12 |
2022-12-30 |
Inserm(法国国家健康医学研究院) |
治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
EP4029501A1
(en)
|
2021-01-19 |
2022-07-20 |
Anagenesis Biotechnologies |
Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
|
|
US20240318256A1
(en)
|
2021-01-29 |
2024-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to diagnose msi cancer
|
|
US20220389104A1
(en)
|
2021-05-28 |
2022-12-08 |
Ose Immunotherapeutics |
Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
|
|
EP4584291A1
(en)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
WO2024061930A1
(en)
|
2022-09-22 |
2024-03-28 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
|
|
WO2024127053A1
(en)
|
2022-12-14 |
2024-06-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to predict a response to immune checkpoint inhibitors in patient with msi cancer
|
|
WO2024161015A1
(en)
|
2023-02-03 |
2024-08-08 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat age-related diseases
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
WO2025114411A1
(en)
|
2023-11-29 |
2025-06-05 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat brain or neurologic disorders
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|